Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is expected to continue its upward trajectory due to its strong financial performance, driven by their unique and effective fertility benefits solutions. With a growing customer base, expanding into new markets, and prioritizing patient experience and partnerships with health plans, the company is well-positioned for long-term success. Its sustained growth, profitability, and superior clinical outcomes give confidence in its potential for continued growth and make it a promising investment opportunity.

Bears say

Progyny is facing increased competition and a shift in purchasing decisions towards measurable outcomes and ROI rather than marketing narratives. Additionally, the company's recent investments in technology infrastructure have impacted margins and may not immediately lead to increased profitability. The company is also facing pressure to maintain high conversion rates and may not be able to sustain its recent levels. These factors contribute to our negative outlook on PGNY's stock.

Progyny (PGNY) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 8 analysts, Progyny (PGNY) has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.